Symbols

TARS

Tarsus·NASDAQ

--(--)

TARS fundamentals

TARS Q4 2025 Earnings

Tarsus (TARS) released its earnings on Feb 23, 2026: revenue was 151.67M (YoY +128.39%), beat estimates; EPS was -0.2 (YoY +66.67%), missed estimates.

Revenue / YoY

151.67M

+128.39%

EPS / YoY

-0.2

+66.67%

Report date

Feb 23, 2026

TARS Earnings Call Summary for Q4,2025

$2B Peak Sales Ambition: XDEMVY targeting $2B U.S. peak sales by 2030+ on 25M DB patients, with 0.5M treated to date.
Pipeline Momentum:
- Ocular rosacea Phase II trial underway, Lyme disease prevention trial launching Q2 2026.
- Global expansion with TP-03 approvals in Japan (2025), Europe (2027).
2026 Growth: $670-700M net sales (+50% YoY), driven by DTC (25% patient awareness) and 15-20 new sales reps.
Financial Discipline: Gross margin ~93%, 2026 R&D spend ~$25M for key trials.

Earnings

EPS

Revenue

Revenue & Expenses

TARS has released its 2025 Q4 earnings report, with revenue of 151.67M, reflecting a YoY change of 128.39%, and net profit of -8.37M, showing a YoY change of 63.77%. The Sankey diagram below clearly presents TARS's revenue sources and cost distribution.

Key Indicators

Tarsus (TARS) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Tarsus (TARS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Tarsus (TARS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Tarsus (TARS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown